美农生物
(301156)
| 流通市值：10.27亿 | | | 总市值：21.68亿 |
| 流通股本：6878.20万 | | | 总股本：1.45亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 97,906,175.23 | 504,419,868.4 | 374,640,349.93 | 222,214,928.01 |
| 营业收入 | 97,906,175.23 | 504,419,868.4 | 374,640,349.93 | 222,214,928.01 |
| 利息收入 | - | 0 | - | - |
| 已赚保费 | - | 0 | - | - |
| 手续费及佣金收入 | - | 0 | - | - |
| 二、营业总成本 | 88,010,714.31 | 446,464,198.73 | 328,431,892.49 | 197,605,663.69 |
| 营业成本 | 70,042,172.29 | 353,441,513.65 | 261,584,951.12 | 157,878,277.13 |
| 利息支出 | 0 | 0 | - | - |
| 手续费及佣金支出 | 0 | 0 | - | - |
| 退保金 | 0 | 0 | - | - |
| 赔付支出净额 | 0 | 0 | - | - |
| 提取保险合同准备金净额 | 0 | 0 | - | - |
| 保单红利支出 | 0 | 0 | - | - |
| 分保费用 | 0 | 0 | - | - |
| 税金及附加 | 555,364.98 | 2,795,631.24 | 1,925,103.91 | 1,250,246.06 |
| 销售费用 | 7,996,293.59 | 37,612,191.79 | 29,169,943.79 | 17,845,985.93 |
| 管理费用 | 6,599,951.21 | 35,446,104.78 | 23,714,421.62 | 15,133,478.1 |
| 研发费用 | 4,123,227.36 | 21,965,539.8 | 16,061,814.55 | 8,658,302.3 |
| 财务费用 | -1,306,295.12 | -4,796,782.53 | -4,024,342.5 | -3,160,625.83 |
| 其中:利息费用 | 12,517.23 | -159,455.94 | -173,958.06 | -189,409.01 |
| 其中:利息收入 | 1,101,651.11 | 3,893,962.47 | 3,084,816.81 | 2,174,180.26 |
| 加:公允价值变动收益 | 535,835.98 | -13,743.65 | 28,394.91 | -137,600 |
| 加:投资收益 | -364,692.95 | 4,113,681.29 | 3,021,464.9 | 1,862,528.79 |
| 净敞口套期收益 | 0 | 0 | - | - |
| 汇兑收益 | 0 | 0 | - | - |
| 资产处置收益 | 0 | 34,978.45 | 10,696.18 | 4,152.97 |
| 资产减值损失(新) | -340,846.43 | -882,636.22 | -219,782.97 | -500,132.34 |
| 信用减值损失(新) | 574,980.06 | 2,834,995.9 | 1,369,132.27 | 1,881,629.42 |
| 其他收益 | 642,004.64 | 2,663,396.39 | 1,761,359.81 | 238,502.71 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 10,942,742.22 | 66,706,341.83 | 52,179,722.54 | 27,958,345.87 |
| 加:营业外收入 | 0 | 3,875,968.69 | 3,875,928.68 | 5,928.68 |
| 减:营业外支出 | 22,153.85 | 362,500.45 | 183,410.53 | 150,834.88 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 10,920,588.37 | 70,219,810.07 | 55,872,240.69 | 27,813,439.67 |
| 减:所得税费用 | 1,336,665.16 | 7,174,497.28 | 6,095,796.82 | 2,720,262.82 |
| 六、净利润 | 9,583,923.21 | 63,045,312.79 | 49,776,443.87 | 25,093,176.85 |
| 持续经营净利润 | 9,583,923.21 | 63,045,312.79 | 49,776,443.87 | 25,093,176.85 |
| 归属于母公司股东的净利润 | 9,583,923.21 | 63,045,312.79 | 49,776,443.87 | 25,093,176.85 |
| (一)基本每股收益 | 0.09 | 0.56 | 0.44 | 0.22 |
| (二)稀释每股收益 | 0.09 | 0.56 | 0.44 | 0.22 |
| 九、综合收益总额 | 9,583,923.21 | 63,045,312.79 | 49,776,443.87 | 25,093,176.85 |
| 归属于母公司股东的综合收益总额 | 9,583,923.21 | 63,045,312.79 | 49,776,443.87 | 25,093,176.85 |
| 公告日期 | 2024-04-25 | 2024-04-09 | 2023-10-27 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |